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OBJECTIVES The goal of this study was to examine the effect of enhanced external counterpulsation
(EECP) on endothelial function.
BACKGROUND Enhanced external counterpulsation improves symptoms and exercise tolerance in patients
with symptomatic coronary artery disease (CAD). However, the exact mechanisms by which
this technique exerts its clinical benefit are unclear.
METHODS Reactive hyperemia-peripheral arterial tonometry (RH-PAT), a noninvasive method to assess
peripheral endothelial function by measuring reactive hyperemic response in the finger, was
performed in 23 patients with refractory angina undergoing a 35-h course of EECP. In each
patient RH-PAT measurements were performed before and after the first, at midcourse, and
the last EECP session. In addition, RH-PAT response was assessed one month after
completion of EECP therapy; RH-PAT index, a measure of reactive hyperemia, was
calculated as the ratio of the digital pulse volume during reactive hyperemia divided by that
at rest.
RESULTS Enhanced external counterpulsation led to symptomatic improvement (1 Canadian Car-
diovascular Society class) in 17 (74%) patients; EECP was associated with a significant
immediate increase in average RH-PAT index after each treatment (p  0.05). In addition,
average RH-PAT index at one-month follow-up was significantly higher than that before
EECP therapy (p  0.05). When patients were divided by their clinical response, RH-PAT
index at one-month follow-up increased only in those patients who experienced clinical
benefit.
CONCLUSIONS Enhanced external counterpulsation enhances peripheral endothelial function with beneficial
effects persisting at one-month follow-up in patients with a positive clinical response. This
suggests that improvement in endothelial function may contribute to the clinical benefit of
EECP in patients with symptomatic CAD. (J Am Coll Cardiol 2003;41:1761–8) © 2003
by the American College of Cardiology Foundation
Enhanced external counterpulsation (EECP) is a noninva-
sive treatment for patients with stable symptomatic coronary
artery disease (CAD) who are not amenable to standard
revascularization procedures, such as percutaneous coronary
intervention and coronary artery bypass graft surgery. Sev-
eral trials have demonstrated that EECP reduces anginal
symptoms in the majority of patients undergoing treatment.
Aside from decreasing angina (1–4) and nitrate use (1,4),
EECP was also shown to increase exercise tolerance (1,5–
8), as well as to prolong the time to exercise-induced
ST-segment depression (6,8,9) and to improve myocardial
perfusion (1,5–8).
The inflation/deflation sequence of EECP leads to an
increase in diastolic aortic pressure, with subsequent in-
crease in coronary perfusion pressure, whereas systolic pres-
sure is reduced, resulting in a diminution of cardiac work-
load (10). In addition, EECP also promotes venous return
leading to an increase in cardiac output of up to 25% (11).
However, little is known about the exact mechanisms by
which these hemodynamic effects translate into clinical
benefit. Improvement in endothelial function has been
suggested as a potential mechanism contributing to the
favorable clinical effect of EECP (11). However, although
an increase in plasma levels of nitric oxide (NO) in response
to EECP, suggesting an improvement in endothelial func-
tion, has been reported (6), little is currently known about
the effect of EECP on endothelium-dependent vasodilatory
capacity.
This study was designed to investigate the effect of EECP
on peripheral endothelial function, as determined by reac-
tive hyperemia-peripheral arterial tonometry (RH-PAT), a
noninvasive plethysmographic technique to assess reactive
hyperemic response in the finger (12–14), in patients with
advanced symptomatic CAD.
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METHODS
Patients and study protocol. This study was approved by
the Mayo Clinic Institutional Review Board. All consecu-
tive patients who were referred for EECP treatment because
of refractory angina and agreed to participate were prospec-
tively enrolled in the study after informed consent was
obtained. As per institutional practice, all patients had
established ischemic CAD and were not amenable to
standard forms of revascularization after review by at least
two cardiologists. Digital deformities and an allergy to latex
were the only exclusion criteria for participation in the
study. All patients underwent a standard 35-h course of
EECP (1 h daily, 5 days a week, over 7 weeks). Acute
hemodynamic effects of EECP, measured as the peak
diastolic-to-systolic pressure ratio (EECP effectiveness ra-
tio), were monitored using conventional finger plethysmog-
raphy (15). Cardiovascular medications remained un-
changed during the duration of the study. For each patient,
all EECP sessions were scheduled at the same time of day
in order to prevent possible effects of circadian variability of
vascular reactivity; RH-PAT measurements were performed
immediately before and after EECP treatment on the first
(session 1), a midcourse (session 17), and the last (session
35) EECP session. In addition, RH-PAT response was
measured at a follow-up visit one month after completion of
the EECP course. Patient demographics were obtained at
baseline. In addition, on all study days, severity of angina
was assessed using the Canadian Cardiovascular Society
(CCS) grading system (16), and cardiovascular functional
status was determined by using the Duke Activity Status
Index (DASI), a self-administered questionnaire assessing
functional capacity that correlates well with objective mea-
sures of maximal exercise capacity (17).
To further document the severity of endothelial dysfunc-
tion in patients undergoing EECP, single RH-PAT mea-
surements were also performed in a control group of seven
healthy individuals without evidence for CAD (mean age,
63  2 years).
RH-PAT. The principle of PAT, a finger plethysmo-
graphic device that allows the isolated detection of pulsatile
arterial volume changes, has been recently described
(12,18,19). This device (Itamar Medical Ltd., Caesarea,
Israel) consists of two finger-mounted probes, which in-
clude a system of inflatable latex air-cushions within a rigid
external case. The probe design allows the application of a
constant and evenly distributed near-diastolic counterpres-
sure within the entire probe, which increases sensitivity by
unloading arterial wall tension, and prevents venous blood
pooling to avoid venoarteriolar reflex vasoconstriction. Pul-
satile volume changes of the fingertip are sensed by a
pressure transducer and transferred to a personal computer
where the signal is band pass-filtered (0.3 to 30 Hz),
amplified, displayed, and stored.
The RH-PAT studies were performed with the patient in
the supine position and both hands on the same level in a
comfortable, thermoneutral environment. A blood pressure
cuff was placed on one upper arm (study arm), while the
contralateral arm served as a control (control arm); RH-
PAT probes were placed on one finger (finger II, III, or IV)
of each hand (same finger on both hands). The fingers on
either side of the one with the probe were separated using
soft sponge rings, and continuous recording of pulsatile
blood volume responses from both hands was initiated.
After a 10-min equilibration period, the blood pressure cuff
on the study arm was inflated to 60 mm Hg above systolic
pressure for 5 min. The cuff was then deflated to induce
RH, whereas PAT recording was continued. Ten minutes
later, the patients were given a single dose of nitroglycerin
(NTG) (0.4 mg, sublingual) to assess endothelium-
independent PAT response, and, after another 10 min,
PAT recording was stopped.
The RH-PAT data were analyzed by a computer in an
operator-independent manner. As a measure of the extent
of RH, the RH-PAT index was calculated as the ratio of the
average amplitude of the PAT signal over a 1-min time
interval starting 1 min after cuff deflation divided by the
average amplitude of the PAT signal of a 3.5-min time
period before cuff inflation (baseline); RH-PAT index
values from the study arm were then normalized to the
control arm to compensate for potential systemic changes.
Hyperemic response to NTG was assessed in a similar
manner. At first, average PAT signal amplitude of four
consecutive 1-min periods starting at 5 min after adminis-
tration of sublingual NTG (5- to 6-min, 6- to 7-min, 7- to
8-min, and 8- to 9-min interval) was calculated; PAT
response to NTG was then calculated as the ratio of the
PAT amplitude of the 1-min interval during which peak
average PAT signal was recorded divided by the amplitude
of the PAT signal at baseline (NTG-PAT index).
Repeatability of RH-PAT results. Repeatability of RH-
PAT measurements was assessed in 28 volunteers (mean
age, 31  1 year; 10 men) on two consecutive days. These
data were analyzed according to the method by Bland and
Altman (20) (Fig. 1).
Statistical analysis. Results are expressed as mean SEM.
Repeated-measures analysis of variance followed by the
Bonferroni t procedure (all pairwise comparison), if indi-
cated, was used to compare continuous data at different
points in time, and Student t test was used to compare
Abbreviations and Acronyms
CAD  coronary artery disease
CCS  Canadian Cardiovascular Society
DASI  Duke Activity Status Index
EECP  enhanced external counterpulsation
eNOS  endothelial nitric oxide synthase
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NO  nitric oxide
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continuous data between different groups. All analyses were
performed using SigmaStat statistical software, version 2.03
(SPSS Inc., Chicago, Illinois). Statistical significance was
accepted for p  0.05.
RESULTS
Patients. Twenty-three patients with advanced symptom-
atic CAD were prospectively studied. The baseline charac-
teristics of these patients are shown in Table 1. All patients
completed their 35-h course of EECP, and 18 patients
returned for a one-month follow-up visit. No major adverse
cardiovascular events were noted during the study period.
EECP and functional class. Thirty-five EECP sessions
led to an improvement by one CCS class in 12 (52%)
patients and by two CCS classes in 5 (22%) patients,
whereas 6 (26%) patients showed no change in CCS class at
the end of EECP treatment. Average CCS class decreased
significantly in response to EECP, an effect that was main-
tained at one month after termination of treatment (Fig. 2).
Similarly, 17 (74%) patients reported an improvement in their
functional status, as measured by the DASI score, during the
course of treatment. Moreover, average DASI score improved
significantly in response to EECP and remained stable at the
one-month follow-up visit (Fig. 2).
Hemodynamic effects of EECP. Average EECP effec-
tiveness ratio achieved at the end of the EECP course did
not differ from that at the beginning of treatment (EECP
day 1: 0.89; EECP day 35: 1.02; p  0.42), and EECP had
no acute or chronic effect on heart rate or blood pressure in
the patients studied.
Effect of EECP on vascular function. Before therapy,
patients undergoing EECP had a significantly lower average
RH-PAT index than healthy control individuals (1.03 
0.04 vs. 1.77 0.18, p 0.001); EECP led to an acute and
significant increase in average RH-PAT index on all three
EECP study days. Moreover, average RH-PAT index was
significantly higher one month after completion of treat-
ment than before initiation of EECP therapy (1.29  0.09
vs. 1.03 0.04; p 0.05) (Fig. 3). In contrast, average peak
PAT response to the nonendothelium-dependent vasodila-
tor NTG was not altered by EECP (Fig. 4).
When the patients were divided into two groups based on
Figure 1. Bland-Altman plot of reactive hyperemia-peripheral arterial tonometry (RH-PAT) repeatability data; RH-PAT index was determined on two
consecutive days among 28 volunteers. The difference between the two paired readings is plotted against their average. The average difference and the upper
and lower limits of agreement (2 SDs of the differences) are indicated.
Table 1. Baseline Characteristics of 23 Patients Undergoing
EECP and RH-PAT Testing
Age, yrs 66  2
Male gender, n (%) 22 (96)
BMI, kg/m2 31.9  0.8
Cardiovascular risk factors
Family history of premature CAD, n (%) 17 (74)
Hypertension, n (%) 16 (69)
Hyperlipidemia, n (%) 20 (87)
Smoking history, n (%) 11 (48)
Diabetes, n (%) 9 (39)
Average total risk factors, n 3.1  0.2
Medication
Beta-blocker, n (%) 23 (100)
Calcium-antagonist, n (%) 13 (57)
ACE inhibitor, n (%) 17 (74)
Nitroglycerin, n (%) 22 (96)
Statin, n (%) 22 (96)
Platelet inhibitor, n (%) 23 (100)
Cardiac history and status
Prior MI, n (%) 17 (74)
Prior coronary revascularization, n (%) 22 (96)
Prior PCI, n (%) 17 (74)
Prior CABG, n (%) 21 (91)
Prior TMR, n (%) 4 (17)
One-vessel disease, n (%) 2 (9)
Two-vessel disease, n (%) 5 (22)
Three-vessel disease, n (%) 16 (69)
Left mainstem disease, n (%) 4 (17)
Prior CHF, n (%) 5 (22)
LVEF, % 47  3
Values are mean  SEM or n (%).
ACE  angiotensin-converting enzyme; BMI  body mass index; CABG 
coronary artery bypass graft surgery; CAD  coronary artery disease; CHF 
congestive heart failure; EECP  enhanced external counterpulsation; LVEF  left
ventricular ejection fraction; MI  myocardial infarction; PCI  percutaneous
coronary intervention; RH-PAT  reactive hyperemia-peripheral arterial tonometry;
TMR  transmyocardial revascularization.
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their clinical response to EECP, RH-PAT index at one-
month follow-up was significantly higher in those patients
who experienced a decrease in CCS class or an increase in
DASI score (Fig. 5).
DISCUSSION
The present study demonstrates that EECP acutely improves
peripheral endothelial function, as measured by RH-PAT, in
patients with advanced CAD. Moreover, it is shown that
patients who experience clinical improvement during EECP
show an additional enhancement of their RH-PAT response
one month after completion of therapy. These data support a
role for an improvement in endothelial function as a mecha-
nism underlying the clinical benefit associated with EECP.
Clinical benefit of EECP. As a result of recent improve-
ments in cardiovascular care, life expectancy of patients with
Figure 2. Effect of enhanced external counterpulsation on average Canadian Cardiovascular Society (CCS) class (A) and average Duke Activity Status Index
(DASI) score (B). *p  0.05 vs. day 1.
Figure 3. Average peripheral arterial tonometry response to reactive hyperemia (RH-PAT index) on the four study days. *p  0.05; †p  0.05 vs.
pre-enhanced external counterpulsation (EECP) RH-PAT indexes on day 1, day 17, and day 35. Open bars  pre-EECP; solid bars  post-EECP.
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CAD will probably continue to increase in the near future.
As a consequence, the cohort of patients who remain
symptomatic despite optimal medical therapy and who are
not amenable to standard revascularization techniques will
likely continue to grow as well (21); EECP represents a
valuable treatment option for these patients. Several trials
have demonstrated that EECP is associated with a positive
clinical response in the majority of CAD patients with
refractory angina undergoing treatment (1–9). Despite
significant cardiac risk profiles and advanced CAD among
patients included in the present study, 74% experienced an
improvement in their functional status in response to EECP,
further supporting the role of EECP as an effective therapeutic
strategy for patients with symptomatic CAD.
EECP and endothelial function. Enhanced external
counterpulsation has been shown to acutely increase blood
flow in various vascular beds, including the coronary arteries
(10,22–25). In the absence of significant arterial obstruc-
tions (26,27), increased blood flow theoretically translates
into enhanced shear stress, which represents a key factor for
endothelial homeostasis (28,29). Thus, given the signifi-
cance of endothelial dysfunction for the development and
Figure 4. Average peripheral arterial tonometry response to the nonendothelium-dependent vasodilator nitroglycerin (NTG-PAT index) on the four study
days, p  0.594 (repeated measures analysis of variance). Open bars  pre-enhanced external counterpulsation (EECP); solid bars  post-EECP.
Figure 5. Average peripheral arterial tonometry response to reactive hyperemia (RH-PAT index) before initiation and one month after completion of
enhanced external counterpulsation (EECP) therapy in patients with or without improvement in functional status. (A) Canadian Cardiovascular Society
(CCS) class; (B) Duke Activity Status Index (DASI) score. *p  0.05 vs. day 1. Open bars  day 1; solid bars  1-month follow-up.
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manifestation of CAD (30), improvement in endothelial
function is an important mechanism by which EECP may
exert its clinical benefit. The fact that patients undergoing
EECP had a significantly lower baseline RH-PAT index
than healthy control individuals, indicating the presence of
endothelial dysfunction, together with the observed en-
hancement in the reactive hyperemic response in EECP-
treated patients in our study, further supports this notion.
Reactive hyperemia, which is due to dilation of small
resistance vessels, is partly mediated by endothelium-
derived NO and, therefore, the magnitude of the hyperemic
response serves as an indicator for the status of endothelial
function (31,32). Moreover, using strain-gauge plethysmog-
raphy, an excellent correlation between peak forearm blood
flow response during RH and that to intra-arterial infusion
of the endothelium-dependent vasodilator acetylcholine has
been demonstrated, indicating that the magnitude of RH
may serve as an index of peripheral endothelial function
(33); RH-PAT permits the noninvasive assessment of
peripheral vascular reactivity by measuring digital pulse
volume at rest and during RH. Notably, although local,
systemic, and environmental factors may modulate digital
pulse volume, this parameter also depends on the bioavail-
ability of NO (34). Moreover, endothelium-derived NO has
been shown to be particularly important for the regulation
of vascular tone in areas rich in arteriovenous anastomoses,
such as the finger tip (35). The effect of NO synthesis
inhibition by N-nitro-L-arginine methyl ester (L-NAME)
on the PAT response to reactive hyperemia was investigated
recently (14). In this study, 19 healthy volunteers underwent
RH-PAT testing, according to the same protocol as was
used in the present study, before and after administration of
L-NAME into the brachial artery. Importantly, L-NAME
administration was associated with a significant 61% reduc-
tion (p  0.05) in the RH-PAT index values, indicating
that this index depends on endothelium-derived NO and,
therefore, represents a marker of peripheral endothelial
function. In accordance with these findings, it was demon-
strated that factors known to affect endothelial function,
including various cardiovascular risk factors and the pres-
ence of CAD, influence RH-PAT index values in a similar
manner as flow-mediated dilation of the brachial artery, a
widely-used method to evaluate peripheral endothelial func-
tion (12). Furthermore, a significant relationship between
the PAT response to reactive hyperemia and flow-mediated
dilation of the brachial artery has been shown, suggesting
that vascular reactivity of the digital vasculature, as mea-
sured by the RH-PAT index, is influenced by endothelial
function in a magnitude and direction similar to that of the
brachial artery (12).
Taken together, we conclude that EECP is associated
with an acute improvement in peripheral endothelial func-
tion, as is demonstrated by the acute increase in RH-PAT
index observed in response to EECP on the first three study
days. Moreover, the significant difference between RH-
PAT indices before the course of EECP and at one-month
follow-up suggests that EECP also exerts a beneficial
medium-term effect on endothelial function, although en-
hanced mobility due to improved functional status in
response to EECP could have contributed to this late effect.
The existence of a beneficial effect on endothelial function is
pointed out further by the observation that the PAT
response to the nonendothelium-dependent vasodilator
NTG was not altered by EECP. Moreover, in line with the
medium-term effect of EECP on endothelial function
observed in the present study are the findings by Masuda et
al. (6), who reported no difference between plasma NO
levels before initiation and one day after completion of a
35-h course of EECP, whereas plasma NO levels were
significantly increased one month after completion of ther-
apy in patients with chronic stable angina. The reason for
the delayed improvement in parameters of endothelial
function may be speculated upon. One possible explanation
is the effect of increased shear stress on the activity and
expression of the enzyme endothelial nitric oxide synthase
(eNOS), the major source of endothelium-derived NO. An
increase in shear stress enhances endothelial NO release via
activation of eNOS through phosphorylation by the serine/
threonine protein kinase Akt (36,37), which represents a
likely mechanism for the acute increase in RH-PAT index
observed in response to EECP. On the other hand, chronic-
intermittent enhancement of shear stress, as generated by a
standard course of EECP, may upregulate eNOS protein
expression (28), which may translate into a delayed, but
prolonged, improvement in endothelial function.
Peripheral effect of EECP. One of the mechanisms by
which EECP may exert its clinical benefit is by increasing
exercise capacity. It may be speculated that EECP may
provide hemodynamic stimuli similar to those of physical
exercise that contribute to the improvement in endothelial
function (38). In line with this concept are the results of
studies showing an enhancement of exercise tolerance,
whereas peak exercise double product is maintained due to
a decrease in maximal blood pressure in some patients after
a course of EECP (5). These results indicate that EECP,
similar to physical training, may promote an exercise-
induced decrease in peripheral vascular resistance. Given the
importance of endothelial function for the regulation of
vascular tone and peripheral vascular resistance, our results
support the notion of the existence of such a peripheral
“training” effect of EECP.
Study limitations. Interventional procedures or the use of
medical devices may be associated with enhanced placebo
effects (39,40). Thus, given the therapeutic principle of
EECP and the lack of an effective (e.g., sham EECP-
treated) control group, the possibility that nonspecific pla-
cebo effects might have contributed to the clinical benefit
observed in the present study cannot definitely be ruled out.
However, the results of the randomized, placebo-controlled
Multicenter Study of Enhanced External Counterpulsation
(MUST-EECP) trial indicated no major role for nonspe-
cific placebo effects as mediators of the clinical benefit
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associated with EECP in patients with angina (9). In
addition, our finding that the delayed increase in reactive
hyperemic response observed during follow-up is restricted
to patients who experience a symptomatic or functional
benefit from EECP therapy supports the hypothesis that
improvement in endothelial function may be an important
mechanism contributing to the clinical benefit associated
with this therapeutic strategy.
The lack of an effective control group also raises the
question as to whether EECP-unrelated factors might have
affected the RH-PAT results. However, on the basis of the
study protocol, patients served as their own controls. Given
that RH-PAT measurements were performed within about
1 h immediately before and after EECP therapy and
without administration of drugs between these paired mea-
surements, an effect of non–EECP-related factors on the
RH-PAT results is rather unlikely. Also, the consistent
effect of EECP on RH-PAT index during the course of
treatment supports the existence of a direct effect of EECP
on digital vasoreactivity.
Conclusions. In summary, the present study suggests that
EECP may improve endothelial function. Aside from an
acute beneficial effect, which occurs immediately after a
therapeutic session, a standard 35-h EECP treatment also
exerts a prolonged favorable effect on endothelial function
that becomes apparent one month after completion of
treatment and is restricted to patients who experience
symptomatic improvement. These results support the no-
tion that improvement in endothelial function may be an
important mechanism by which EECP exerts its clinical
benefit.
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